Find resources

Total results with these characteristics: 51

Disease: Respiratory syncytial virus (RSV)

Page 1 of 3
Acute Respiratory Infections (Update September 2009): Respiratory syncytial virus and parainfluenza viruses

This page on the World Health Organization website provides information on respiratory syncytial virus (RSV) and parainfluenza viruses, including the RSV disease burden, virology, and vaccines under development.

Author: World Health Organization

Publication date: 2009

Architecture of Respiratory Syncytial Virus Revealed by Electron Cryotomography

This article, published in the Proceedings of the National Academy of Sciences of the United States of America, describes research to carry out an electron cryotomographic characterization of cell culture-grown human respiratory syncytial virus to …

Author: Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ

Publication date: 2013

Biological Challenges and Technological Opportunities for Respiratory Syncytial Virus Vaccine Development

This article, published in Immunological Reviews, provides an overview of the barriers that have challenged and delayed the development of vaccines against respiratory syncytial virus (RSV) and identifies opportunities that could help overcome these …

Author: Graham B

Publication date: 2011

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

This article, published in The Journal of Infectious Diseases, summarizes two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, that brought together academic, public health, and …

Author: Simões EAF, DeVincenzo JP, Boeckh M, et al.

Publication date: 2015

Challenges in Developing a Pediatric RSV Vaccine

There is currently no approved respiratory syncytial virus (RSV) vaccine, and the goal of preventing RSV-associated illness in the general population remains unmet. The authors of this article, published in Human Vaccines, discuss the challenges …

Author: Schickli JH, Dubovsky F, Tang RS

Publication date: 2009

Clinical and Epidemiologic Features of Respiratory Syncytial Virus

This book chapter, published in Current Topics in Microbiology and Immunology, provides an overview of the symptoms and epidemiology for respiratory syncytial virus (RSV) and identifies four potential target populations for a vaccine—infants, …

Author: Hall CB, Simões EAF, Anderson LJ

Publication date: 2013

Correlates of Immunity to Respiratory Syncytial Virus (RSV) Associated-Hospitalization: Establishment of Minimum Protective Threshold Levels of Serum Neutralizing Antibodies

This article, published in Vaccine, reports on a study to determine if respiratory syncytial virus (RSV) specific, serum antibody titers correlate with protection against RSV-associated hospitalization at all ages. The authors identified a minimal …

Author: Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP

Publication date: 2003

Cotton Rats Previously Immunized With a Chimeric RSV FG Glycoprotein Develop Enhanced Pulmonary Pathology When Infected With RSV, a Phenomenon not Encountered Following Immunization With Vaccinia-RSV Recombinants or RSV

In studies conducted in the 1960s, children previously immunized with a formalin-inactivated respiratory syncytial virus (RSV) vaccine (FI-RSV) developed a greater incidence and severity of pulmonary disease during subsequent natural RSV infection …

Author: Connors M, Collins PL, Firestone CY, et al.

Publication date: 1992

Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus

This article, published in The Journal of Infectious Diseases, details a preclinical study evaluating the ability of a humanized monoclonal antibody, MEDI-493 (later named palivizumab and marketed at Synagis®), to recognize a conserved …

Author: Johnson S, Oliver C, Prince GA, et al.

Publication date: 1997

Disability-Adjusted Life Years (DALYs) for 291 Diseases and Injuries in 21 Regions, 1990–2010: A Systematic Analysis for the Global Burden of Disease Study 2010

This article, published in The Lancet, shares results from the Global Burden of Disease Study, calculating disease burden using disability-adjusted life years (DALYs) both worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable …

Author: Murray CJL, Vos T, Lozano R, et al.

Publication date: 2012

Dissociation Between Serum Neutralizing and Glycoprotein Antibody Responses of Infants and Children Who Received Inactivated Respiratory Syncytial Virus Vaccine

In the 1960s a respiratory syncytial virus (RSV) vaccine was evaluated in infants and young children. Vaccinees who received formalin-inactivated RSV during early infancy developed more serious lower-respiratory-tract disease when infected with the …

Author: Murphy BR, Prince GA, Walsh EE, et al.

Publication date: 1986

Enhanced Pulmonary Histopathology is Observed in Cotton Rats Immunized with Formalin-Inactivated Respiratory Syncytial Virus (RSV) or Purified F Glycoprotein and Challenged With RSV 3-6 Months After Immunization

The authors of this study, published in Vaccine, compared formalin-inactivated (FI) RSV, purified F glycoprotein in alum, and RSV infection (intranasal) for their immunogenicity, efficacy, and ability to enhance pulmonary histopathology during RSV …

Author: Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA

Publication date: 1990

An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine

This article, published in the American Journal of Epidemiology, describes a study that evaluated altered clinical reactivity to a formalin-inactivated respiratory syncytial virus (RSV) vaccine candidate administered to healthy infants and children …

Author: Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE

Publication date: 1969

Epidemiology, Aetiology and Management of Childhood Acute Community-Acquired Pneumonia in Developing Countries--A Review

This article, published in the African Journal of Medicine and Medical Sciences, provides an overview of the causes of clinical pneumonia in developing countries, available vaccines for fighting pneumonia, and efforts underway and planned to expand …

Author: Falade AG, Ayede AI

Publication date: 2011

Field Evaluation of a Respiratory Syncytial Virus Vaccine and a Trivalent Parainfluenza Virus Vaccine in a Pediatric Population

This article, published the American Journal of Epidemiology, describes a field study conducted in California, United States, that evaluated two formalin inactivated respiratory virus vaccines, a respiratory syncytial virus (RSV) vaccine and a …

Author: Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH

Publication date: 1969

Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010

This article, published in The Lancet, reports on the results of the Global Burden of Diseases, Injuries, and Risk Factors Study 2010, which aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes. The …

Author: Lozano R, Naghavi M, Foreman K, et al.

Publication date: 2012

Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-analysis

This article, published in The Lancet, describes research to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to respiratory syncytial virus (RSV) in children younger than five years …

Author: Nair H, Nokes DJ, Gessner BD, et al.

Publication date: 2010

Hot Topics in the Prevention of Respiratory Syncytial Virus Disease

This article, published in Expert Review of Vaccines, summarizes the proceedings from the 7th International Respiratory Syncytial Virus (RSV) Symposium, which convened approximately 200 clinicians, scientists, and industry representatives from …

Author: Habibi MS, Patel S, Openshaw P

Publication date: 2011

Increasing Access to Lifesaving Vaccines: PATH Closes the Immunization Gap Through Innovation and Collaboration

This fact sheet outlines PATH's work on vaccines and immunization. Topic areas include developing affordable vaccines, designing innovative vaccine technologies, and expanding uptake of existing vaccines. These efforts reduce the burden of malaria, …

Author: PATH

Publication date: 2013

Jordan Report: Accelerated Development of Vaccines 2012

This comprehensive report includes expert articles on a variety of vaccine-related topics and updates on vaccine research for specific infectious diseases, such as influenza, malaria, respiratory syncytial virus, and rotavirus.

Author: US National Institute of Allergy and Infectious Diseases

Publication date: 2012

Landscape Analysis: Trends in Vaccine Availability and Novel Vaccine Delivery Technologies: 2008–2025

This landscape analysis identifies trends in the availability of vaccines and novel vaccine delivery technologies that are and will be of relevance to low- and middle-income countries from the present through 2025.

Author: PATH, World Health Organization

Publication date: 2008

Maternal Immunization Against Viral Disease

This article, published in Vaccine, discusses the advantages and disadvantages of maternal immunization to augment the protective effect of maternal antibody against many viral diseases in the young infant. The authors also present more specific …

Author: Englund J, Glezen WP, Piedra PA

Publication date: 1998

Microneutralization Test for Respiratory Syncytial Virus Based on an Enzyme Immunoassay

This article, published in the Journal of Clinical Microbiology, details a method to test for respiratory syncytial virus using an enzyme-linked immunosorbant assay. The technique allows large numbers of neutralization tests to be run and automates …

Author: Anderson LJ, Hierholzer JC, Bingham PG, Stone YO

Publication date: 1985

Neutralizing Antibodies Against the Preactive Form of Respiratory Syncytial Virus Fusion Protein Offer Unique Possibilities for Clinical Intervention

The only specific treatment available today against human respiratory syncytial virus (hRSV) is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe …

Author: Magro M, Mas V, Chappell K, et al.

Publication date: 2012

Passive Protection Against Respiratory Syncytial Virus Disease in Infants: the Role of Maternal Antibody

Respiratory syncytial virus (RSV) is responsible for serious respiratory disease in young infants. The authors of this article, published in The Pediatric Infectious Disease Journal, discuss the importance of maternal antibody in the immunity …

Author: Englund JA

Publication date: 1994

Page 1 of 3